Thomas D B, Noonan L, Whitehead A
Bull World Health Organ. 1985;63(3):513-9.
The preliminary results of a study of the incidence of breast cancer in relation to use of depot-medroxyprogesterone acetate (DMPA) are presented. The findings are based on data from three participating centres in Thailand, and one each in Kenya and Mexico. A relative risk for breast cancer of 0.7 was observed in women who had ever used DMPA; this was not statistically significant. Although no consistent decrease in risk with duration of use was observed, the lowest relative risk (0.5) was observed in women who had used DMPA for three or more years. These findings are based on small numbers and must be considered preliminary. However, they provide no evidence that DMPA increases the risk of breast cancer, and suggest that it may exert a protective effect, particularly in long-term users.
本文呈现了一项关于醋酸甲羟孕酮长效注射剂（DMPA）使用与乳腺癌发病率关系的研究初步结果。这些发现基于泰国三个参与中心以及肯尼亚和墨西哥各一个中心的数据。曾使用过DMPA的女性患乳腺癌的相对风险为0.7；这在统计学上不显著。尽管未观察到风险随使用时长呈持续下降，但在使用DMPA三年及以上的女性中观察到了最低的相对风险（0.5）。这些发现基于少量样本，必须视为初步结果。然而，它们并未提供证据表明DMPA会增加乳腺癌风险，反而表明其可能具有保护作用，尤其是对长期使用者。
